Syndax Pharmaceuticals — Third Quarter 2026 Earnings Summary

Syndax Pharmaceuticals reported total revenue of $83.3 million for the third quarter of 2026, representing an 82% year-over-year increase driven by $60.7 million in Revuforj net revenue and $22.6 million in collaboration revenue from Niktimvo. Revuforj sales grew 90% year-over-year with a 20% increase in new patients, while Niktimvo revenue rose 47% year-over-year as the company co-commercializes the therapy with Incyte. The company announced a leadership change with Aaron Ondrey replacing Keith Goldan as Chief Financial Officer and expects to initiate the RAVEN and MenTain clinical trials in late 2026 and early 2027, respectively. Additionally, Syndax reported a net loss of $49.4 million for the quarter and maintains a cash position of $551.1 million as it advances multiple pipeline assets including SNDX-4321 and SNDX-62122.